Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics director Kenneth Carl Anderson exercised stock options to acquire 1,070 shares of common stock on June 1, 2026. The options were exercised at a price of $2.11 per share for cash, and no shares were sold in connection with the exercise.
Following the exercise, Anderson directly holds 69,300 shares of C4 Therapeutics common stock. Additional shares are held indirectly through several revocable and irrevocable trusts associated with Anderson and Cynthia E. Anderson, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
CCCC reported a same-day exercise-and-sale of stock options granted under its 2020 Equity Incentive Plan. The filing states 29,080 options were granted on 02/14/2025; of those, 9,087 vested and were exercised and sold pursuant to a same-day sale transaction. The filing lists brokerage details for the transaction.
C4 Therapeutics, Inc. Schedule 13G: Squadron Master Fund LP and affiliated filers report beneficial ownership of 5,550,000 shares of common stock, representing 5.0% of the class based on 110,567,222 shares outstanding as of May 1, 2026.
The filing states the holdings reflect shared voting and dispositive power and includes a Rule 13d-4 disclaimer that the adviser and named partners disclaim beneficial ownership.
C4 Therapeutics, Inc. ownership disclosure: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared beneficial ownership of 169,096 shares of Common Stock, representing 0.2% of the class, as of the close of business on March 31, 2026.
The filing states these reporting persons own no shares directly and that shared voting and dispositive power over the reported shares is held through investment funds and management arrangements. The statement disclaims that this filing should not be construed as admission of beneficial ownership for purposes of Section 13.
C4 Therapeutics reported a change in its senior finance leadership roles. The company determined that Mark Mossler will no longer serve as Chief Accounting Officer, effective May 15, 2026, and stated that his departure does not involve any disagreement about financial reporting, operations, policies or practices.
Kendra R. Adams, currently Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the company’s principal accounting officer, also effective May 15, 2026. She will not receive additional compensation for this role, and no existing plans or arrangements involving her have been changed.
C4 Therapeutics reports that Sirenia Capital Management and Alex Silverstein collectively beneficially own 23,505,000 shares of Common Stock, representing 9.9% of the class after applying a 9.99% ownership blocker.
The filing states the percentage is calculated using 97,578,175 shares outstanding as of February 23, 2026 and notes that the reported holdings include 14,170,000 shares issuable upon exercise of warrants subject to the 9.99% Blocker; as a result, the Reporting Persons cannot currently exercise all warrants because of that limitation.
C4 Therapeutics reported a first‑quarter 2026 net loss of $25.1 million, slightly improved from $26.3 million a year earlier, as collaboration revenue was $6.2 million and operating expenses eased modestly. Cash, cash equivalents and marketable securities totaled $268.3 million as of March 31, 2026, which management believes will fund operations for at least 12 months.
The company continues to focus on targeted protein degradation, advancing lead drug cemsidomide in multiple myeloma through a Phase 2 trial and a Phase 1b combination study with elranatamab. Lung cancer candidate CFT8919 is in Phase 1 in Greater China via Betta Pharma. Collaborations with Roche, Biogen, Betta Pharma and MKDG provided milestone and research revenue, including a $2.0 million Biogen milestone in the quarter, and a new April 2026 Roche DAC agreement added a $20.0 million upfront payment and more than $1.0 billion in potential milestones.
C4 Therapeutics reported first quarter 2026 results and highlighted progress in its protein degrader pipeline. Revenue was $6.2 million, down from $7.2 million a year earlier, mainly reflecting the conclusion and reprioritization of Merck collaborations. R&D expense declined to $24.6 million from $27.1 million, while G&A expense remained steady at $9.3 million.
Net loss narrowed slightly to $25.1 million, or $0.20 per share, compared with $26.3 million, or $0.37 per share, in the prior-year quarter. Cash, cash equivalents and marketable securities were $268.3 million as of March 31, 2026, and the company expects this to fund operations to the end of 2028.
The company advanced cemsidomide in multiple myeloma with Phase 2 and Phase 1b trials enrolling and plans an additional Phase 1b combination trial in 2027. It also expanded its long-term partnership with Roche through a new degrader‑antibody conjugate collaboration, including a $20 million upfront payment, and decided not to advance CFT8919 in non-small cell lung cancer outside Greater China.
C4 Therapeutics (CCCC) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, describing a clinical-stage biopharmaceutical company advancing targeted protein degraders via its proprietary TORPEDO platform. The report highlights two clinical programs—cemsidomide (IKZF1/3) in multiple myeloma and CFT8919 (EGFR L858R) in NSCLC—and partnerships with Merck KGaA, Roche, Betta Pharma, Pfizer, and Biogen. Management reports net losses of $105.0M in 2025 and $105.3M in 2024, a market value of $100.05M for non-affiliate equity as of June 30, 2025, and 97,578,175 shares outstanding as of February 23, 2026. The filing outlines R&D strategy, collaboration payments and milestones, intellectual property positions, manufacturing reliance on CMOs, and regulatory pathways for oncology and CNS programs.
C4 Therapeutics is asking stockholders to vote at its 2026 virtual annual meeting on four items: electing three Class III directors, an advisory vote on executive pay, ratifying KPMG as auditor, and amending the 2020 Stock Option and Incentive Plan’s evergreen provision to count pre-funded warrants.
The proxy highlights 2025 progress, including advancing lead degrader cemsidomide into Phase 2 and Phase 1b multiple myeloma studies, launching a new discovery strategy in inflammation, neuroinflammation and neurodegeneration, and deepening collaborations with Biogen, Merck KGaA and Roche. The company also raised $125 million in an underwritten offering, extending its cash runway to the end of 2028.